ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Prevalence, risk factors and adverse health outcomes of osteosarcopenia in middle-aged and older adults with type 2 diabetes mellitus-a scoping review.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis and sarcopenia are increasingly recognised as important complications of type 2 diabetes mellitus (T2D). As both conditions share common pathophysiological mechanisms, they can coexist in the same individual. The coexistence of osteoporosis and sarcopenia, known as osteosarcopenia (OS), is an emerging geriatric syndrome. Compared with its individual components, OS has received much less attention. The overall objective of this scoping review was to summarise the existing literature on the prevalence, risk factors, biomarkers, and adverse health outcomes associated with OS in adults with T2D aged ≥ 40. A search was conducted in eight online databases (Ovid MEDLINE®, Embase (Ovid), PubMed, CINAHL, Cochrane Library, Web of Science, Scopus and PsycINFO) and grey literature sources for relevant articles published in English up to 31 July 2024. A total of ten articles reporting findings from nine distinct studies (7 cross-sectional, 2 case-control) were included. Despite significant heterogeneity in its definition, OS was shown to be prevalent in T2D. The risk of OS was increased in individuals with T2D who had poor β-cell function, low body mass index, and smaller waist circumference. Insulin resistance, duration of T2D, glycaemic control, and metformin, sulfonylurea and insulin use were not shown to be significant risk factors. Osteocalcin was a potentially useful biomarker of OS in T2D, and OS may be associated with falls and leg fractures in T2D. In conclusion, this scoping review revealed a paucity of information about OS in T2D. Longitudinal studies with comprehensive phenotyping are required to address the many knowledge gaps.
Indexed as
Identifiers
42828564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.